Kelly L. Stratton, MD, FACS, highlights 5 pivotal prostate cancer studies from the 2022 ASCO Genitourinary Cancers Symposium.
In this video, Kelly L. Stratton, MD, FACS, highlights notable prostate cancer research being presented at the 2022 ASCO Genitourinary Cancers Symposium. Stratton is an assistant professor of urologic oncology at the University of Oklahoma, Oklahoma City.
The following 5 abstracts are summarized:
Abstract 11: PROpel: Phase III trial of olaparib and abiraterone versus placebo and abiraterone as first-line therapy for patients with metastatic castration-resistant prostate cancer
Abstract 12: Phase III MAGNITUDE study: First results of niraparib with abiraterone acetate and prednisone as first-line therapy in patients with mCRPC with and without homologous recombination repair gene alterations.
Abstract 13: Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial.
Abstract 9: Detection rate of 18F-rhPSMA-7.3 PET in patients with suspected prostate cancer recurrence: results from a phase 3, prospective, multicenter study (SPOTLIGHT)
Abstract 15: A randomized, double-blind, placebo-controlled, phase 3b study of the efficacy and safety of continuing enzalutamide in chemotherapy-naïve, metastatic castration-resistant prostate cancer patients treated with docetaxel plus prednisolone who have progressed on enzalutamide: PRESIDE.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.